Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/14638
ชื่อเรื่อง: Intratympanic dexamethasone for refractory sudden sensorineural hearing loss
ผู้แต่ง: Hunchaisri N.
Chantapant S.
Srinangyam N.
Keywords: betahistine
cyanocobalamin
dexamethasone
mecobalamin
prednisolone
pyridoxine
thiamine
adolescent
adult
aged
article
clinical article
clinical trial
controlled clinical trial
controlled study
drug efficacy
drug response
eardrum perforation
female
human
infection
male
pain
perception deafness
prospective study
sudden deafness
treatment outcome
vertigo
Administration, Oral
Administration, Topical
Adolescent
Adult
Aged
Aged, 80 and over
Anti-Inflammatory Agents
Audiometry, Pure-Tone
Auditory Threshold
Dexamethasone
Dose-Response Relationship, Drug
Female
Hearing Loss, Sensorineural
Hearing Loss, Sudden
Humans
Male
Middle Aged
Prednisolone
Prospective Studies
Treatment Outcome
Tympanic Membrane
Young Adult
วันที่เผยแพร่: 2010
บทคัดย่อ: Background: The standard medical regimen for SSNHL is systemic steroid therapy. Unfortunately, some patients either do not or poorly respond to systemic steroids. Intratympanic administration of steroids has been suggested as an alternative to systemic therapy. Objective: To determine if intratympanic dexamethasone injection (ITDI) is an effective treatment for sudden sensorineural hearing loss (SSNHL) in patients that systemic steroid treatment has failed. Material and Method: A prospective, non-randomized, controlled study evaluated the hearing outcomes in 14 SSNHL patients treated with ITDI as compared with the outcome of seven patients not treated. Int ratympanic dexamethasone was administered through a spinal needle under local anesthesia. ITDI was performed once every week for maximum of three sessions. Hearing was assessed immediately before the therapy and 4 weeks after the therapy. Results: Hearing improvement was documented in six of 14 patients (43%) who underwent ITDI compare to none of the seven patients (0%) in no ITDI group. However, this was not statistically significant (p = 0.055). Conclusion: Intratympanic dexamethasone (ITDI) may have benefits for patients with SSNHL who failed systemic steroid therapy.
URI: https://ir.swu.ac.th/jspui/handle/123456789/14638
https://www.scopus.com/inward/record.uri?eid=2-s2.0-78650054054&partnerID=40&md5=3ec54880df8d7c2ff93bfc42822c2b1f
ISSN: 1252208
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.